Custom knee implants put to the test against standard ones

NCT ID NCT02494544

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether custom-made knee implants (ConforMIS iTotal) help people move better than standard off-the-shelf implants after knee replacement surgery. About 215 adults with osteoarthritis took part. Researchers measured walking, daily activities, and sports performance to see which implant worked best.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

215 people

The number who actually took part.

Started

Jul 2015

Finished

Nov 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion: * Clinical condition included in the approved Indications For Use for the iTotal CR * Osteoarthritis, as confirmed by the investigator's assessment of disease status at screening visit that warrants a TKR procedure. Disease status is assessed by Clinical and Radiographic assessment * Willingness to participate in the clinical study, to give informed consent and to attend all follow-up visits * \> 18 years of age Exclusion: * Subject will require a simultaneous bilateral procedure * Other lower extremity surgery within 1 year * Severe (\> 15º) fixed valgus or varus deformity * Severe (\> 15º) extension deficit * Severe instability due to advanced loss of osteochondral structure * Loss of bone or musculature, osteoporosis, neuromuscular or vascular compromise in the area of the joint to be operated on to an extent that the procedure is unjustified * Insufficient bone stock on the femoral or tibial surfaces * Contralateral knee replacement surgery within the past 6 months * BMI \> 40 * Active malignancy (defined as a history of any invasive malignancy - except non-melanoma skin cancer), unless patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years * Poorly controlled diabetes (defined as HbA1c \>7 or surgeon discretion) * Immunocompromised * Other physical disability affecting the hips, spine, or contralateral knee that limits function * Disabling chronic pain with narcotic dependence * Compromised PCL or collateral ligament * Prior history of failed implant surgery of the joint to be treated, including Unicompartmental Knee Arthroplasty (UKA), or Bicompartmental Knee Arthroplasty (BKA) * Prior history of failed high tibial osteotomy (HTO) * Participation in another clinical study which would confound results * Inability to complete the protocol in the opinion of the clinical staff due to safety or other reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Denver-Vail Orthopedics

    Parker, Colorado, 80134, United States

  • OrthoNY

    Albany, New York, 12205, United States

  • Sharp Healthcare

    San Diego, California, 92123, United States

  • The Lindner Center for Research and Education

    Cincinnati, Ohio, 45219, United States

  • Tufts University

    Boston, Massachusetts, 02111, United States

  • University of California in San Diego

    La Jolla, California, 92037, United States

  • University of Missouri

    Columbia, Missouri, 65212, United States

  • Yale School of Medicine

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.